Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug cocktail aims to boost mesothelioma surgery success

NCT ID NCT03228537

Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 4 times

Summary

This early-phase trial is testing whether adding the immunotherapy drug atezolizumab to standard chemotherapy (cisplatin and pemetrexed) before and after surgery can help people with resectable pleural mesothelioma. The study includes 28 participants with stage I-III disease. The main goals are to see if the treatment plan is feasible and safe, not yet to prove it works better than existing options.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
atezolizumab (immunotherapy) plus cisplatin and pemetrexed (chemotherapy)
What this could lead to
If this approach works, it could improve outcomes for people with resectable mesothelioma by shrinking tumors before surgery and clearing remaining cancer cells afterward.
What could go wrong
This is a very early, small phase 1 trial focused on feasibility and safety, not effectiveness. The combination may cause serious immune-related side effects, and results may not apply to all mesothelioma types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

28 people

The number who actually took part.

Started

Jul 2018

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

A government research agency

The lead sponsor is the US National Institutes of Health.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * STEP 1: NEOADJUVANT * Patient must have stage I-III malignant pleural mesothelioma that is deemed resectable and must be planning to undergo pleurectomy decortication (P/D) or extrapleural pneumonectomy (EPP) * Patient must have epithelioid or biphasic histology (sarcomatoid histology is excluded); histologic diagnosis and typing of mesothelioma requires at least a core needle biopsy or surgical biopsy of the pleura via thoracoscopy and small thoracotomy; cytology only will not be regarded as sufficient for the diagnosis * Patient must have computed tomography (CT) chest/abdomen/pelvis with contrast or fludeoxyglucose F-18 (FDG)-positron emission tomography (PET)/CT scan performed within 28 days prior to step 1 registration * Patients must have non-measurable or measurable disease documented by CT or magnetic resonance imaging (MRI); the CT from a combined PET/CT may be used to document only non-measurable disease unless it is of diagnostic quality; measurable disease must be assessed within 28 days prior to step 1 registration; non-measurable disease must be assessed within 42 days prior to step 1 registration; all disease must be assessed and documented on the RECIST 1.1 and modified RECIST baseline tumor assessment form * Patient must have undergone extended surgical staging including mediastinoscopy or endobronchial ultrasound; at minimum, samples must be obtained from the mediastinal stations 4R, 7 (subcarinal), and 4L; this surgical staging must be performed within 42 days prior to step 1 registration; patient must be T1-3 and N0-N2 (single station) * Patient must undergo video-assisted thoracoscopic surgery and diagnostic laparoscopy within 28 days prior to step 1 registration to rule out peritoneal disease spread * Patient must have consultation with a surgeon within 21 days prior to step 1 registration; the surgeon must confirm that the patient's disease is resectable by pleurectomy decortication (P/D) or extrapleural pneumonectomy (EPP) and that the patient is an appropriate candidate for the surgical procedures * Patient must not have had prior immunotherapy or chemotherapy for malignant pleural mesothelioma * Patient must have Zubrod performance status 0 or 1 documented within 28 days prior to step 1 registration * Patients requiring hearing aids or reporting hearing loss must have audiogram performed within 28 days prior to step 1 registration * Patient must have not had any major surgery or radiation within 28 days prior to step 1 registration; diagnostic thoracotomies and laparoscopies are not considered major surgeries * Patients must not have any anticancer therapy or investigational agent within 28 days prior to step 1 registration * Absolute neutrophil count (ANC) \>= 1,500/mcl (documented within 28 days prior to step 1 registration) * Hemoglobin \>= 9 g/dl (documented within 28 days prior to step 1 registration) * Platelets \>= 100,000/mcl (documented within 28 days prior to step 1 registration) * Creatinine =\< 1.5 x upper limit of normal (ULN) (documented within 28 days prior to step 1 registration) * Creatinine clearance \>= 45 ml/min (documented within 28 days prior to step 1 registration) * Total bilirubin =\< 1.5 x upper limit of normal (ULN) (within 28 days prior to step 1 registration) * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 3 x ULN (within 28 days prior to step 1 registration) * No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for three years * Patients must not be pregnant or nursing due to the potential teratogenic side effects of the protocol treatment; women of reproductive potential and men must have agreed to use an effective contraceptive method for the duration of study treatment and for 5 months (150 days) after the last dose of atezolizumab; a woman is considered to be of "reproductive potential" if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, "effective contraception" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures * Patient must NOT have a history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins * Patient must NOT have a known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation * Patients must not have severe infections within 28 days prior to step 1 registration, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia * Patients must not have active autoimmune disease that has required systemic treatment in past two years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs); replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment; autoimmune diseases include, but are not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Bell's palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis; this protocol includes an immunotherapy agent which can precipitate known autoimmune diseases * Patients must not have undergone prior allogeneic bone marrow transplantation or prior solid organ transplantation * Patient must not have active tuberculosis * Patient must not have history of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis; this protocol includes an immunotherapy agent which can precipitate known pneumonitis * Patient must not have active (chronic or acute) hepatitis B virus (HBV) infection as evidenced by testing performed within 28 days prior to registration; patients with past or resolved HBV infection are eligible; active HBV is defined as having a positive hepatitis B surface antigen (HBsAg) test; past or resolved HBV is defined as having a negative HBsAG test and a positive total hepatitis B core antibody (HBcAb) test; patient must not have active hepatitis C virus (HCV) infection as evidenced by testing performed within 28 days prior to registration; active HCV is defined as having a positive HCV antibody test followed by a positive HCV RNA test * Patient must NOT have a known positive test for human immunodeficiency virus (HIV); patients do not need to be screened for HIV; patients with HIV are excluded due to a potential incompetent immune system and need for medications that could interfere with the treatment and immunotherapy * Patient must not have significant cardiovascular disease, such as New York Heart Association cardiac disease (class II or greater), myocardial infarction within 3 months prior to initiation of treatment, unstable arrhythmias, or unstable angina given the higher risks associated with surgical resection * Patient must not receive live, attenuated influenza vaccine within 4 weeks prior to registration or at any time during the study and until 5 months after the last dose of atezolizumab * Patient must be willing to have tissue specimens submitted for translational medicine studies * Patient must be offered the opportunity to participate in tissue and blood banking for future studies * Patient must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines * As a part of the Oncology Patient Enrollment Network (OPEN) registration process, the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system * STEP 2: SURGERY * Patient must have a CT of chest/abdomen with contrast or FDG-PET/CT scan within 28 days prior to step 2 registration; patients must not have evidence of progression per RECIST 1.1 or modified RECIST for pleural tumors * Patients planning to receive EPP must also be evaluated for appropriateness of radiation therapy (RT) by a radiation oncologist within 14 days prior to step 2 registration * Patients must have a Zubrod performance status of 0-1 documented within 28 days prior to step 2 registration * Patients must have postoperative predicted forced expiratory volume in 1 second (FEV1) \> 35% prior to surgery obtained within 28 days prior to step 2 registration; pulmonary function tests to ascertain these values must be obtained within 28 days prior to Step 2 registration * Patients must have postoperative predicted carbon monoxide diffusing capability (DLCO) \> 35% prior to surgery obtained within 28 days prior to step 2 registration; pulmonary function tests to ascertain these values must be obtained within 28 days prior to Step 2 registration * Patient must have received at least two cycles of triplet neoadjuvant therapy (all three drugs) during step 1 * Patient must be registered to step 2 no less than 21 days and no more than 90 days after the end of their final cycle of neoadjuvant therapy * STEP 3: MAINTENANCE * Patient must have received either P/D or EPP and must have recovered from all effects of surgery with adequate wound healing; patients who received radiation therapy (RT) must be registered to step 3 within 90 days after discontinuing RT; patients who did not receive RT must be registered to step 3 within 90 days after surgery * Patient must have a CT of chest/abdomen/pelvis with contrast or FDG-PET/CT scan within 28 days prior to step 3 registration; patient must not have evidence of progression per RECIST 1.1 or modified RECIST for pleural tumors * Patient may have discontinued RT early due to toxicity or other reasons * Patients must have a Zubrod performance status of 0-1 documented within 28 days prior to step 3 registration * ANC \> 1,500/mcl (documented within 28 days prior to step 3 registration) * Hemoglobin \> 9 g/dl (documented within 28 days prior to step 3 registration) * Platelets \> 100,000/mcl (documented within 28 days prior to step 3 registration) * Creatinine \< 1.5 x ULN (documented within 28 days prior to step 3 registration) * Total bilirubin =\< 1.5 x upper limit of normal (ULN) (within 28 days prior to step 3 registration) * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 3 x ULN (within 28 days prior to step 3 registration)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Biphasic mesothelioma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

malignant biphasic mesothelioma malignant epithelioid mesothelioma malignant pleural mesothelioma Mesothelioma, Malignant

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Biphasic mesothelioma Epithelioid mesothelioma Stage I pleural diffuse malignant mesothelioma ajcc V7 Stage I pleural malignant mesothelioma ajcc V7 Stage IA pleural diffuse malignant mesothelioma ajcc V7 Stage IA pleural malignant mesothelioma ajcc V7 Stage IB pleural diffuse malignant mesothelioma ajcc V7 Stage IB pleural malignant mesothelioma ajcc V7 Stage II pleural diffuse malignant mesothelioma ajcc V7 Stage II pleural malignant mesothelioma ajcc V7 Stage III pleural diffuse malignant mesothelioma ajcc V7 Stage III pleural malignant mesothelioma ajcc V7

Contacts and locations

Locations

  • AdventHealth Littleton

    Littleton, Colorado, 80122, United States

  • AdventHealth Parker

    Parker, Colorado, 80138, United States

  • AdventHealth Porter

    Denver, Colorado, 80210, United States

  • Alegent Health Bergan Mercy Medical Center

    Omaha, Nebraska, 68124, United States

  • Alegent Health Immanuel Medical Center

    Omaha, Nebraska, 68122, United States

  • Alegent Health Lakeside Hospital

    Omaha, Nebraska, 68130, United States

  • Alegent Health Mercy Hospital

    Council Bluffs, Iowa, 51503, United States

  • Allegiance Health

    Jackson, Michigan, 49201, United States

  • Alliance for Childhood Diseases/Cure 4 the Kids Foundation

    Las Vegas, Nevada, 89135, United States

  • Ascension Via Christi Hospitals Wichita

    Wichita, Kansas, 67214, United States

  • Baptist MD Anderson Cancer Center

    Jacksonville, Florida, 32207, United States

  • Benefis Sletten Cancer Institute

    Great Falls, Montana, 59405, United States

  • Bethesda North Hospital

    Cincinnati, Ohio, 45242, United States

  • Billings Clinic Cancer Center

    Billings, Montana, 59101, United States

  • Billings Clinic-Cody

    Cody, Wyoming, 82414, United States

  • Bozeman Health Deaconess Hospital

    Bozeman, Montana, 59715, United States

  • CHI Health Good Samaritan

    Kearney, Nebraska, 68847, United States

  • CHI Saint Vincent Cancer Center Hot Springs

    Hot Springs, Arkansas, 71913, United States

  • Cancer Care Center of O'Fallon

    O'Fallon, Illinois, 62269, United States

  • Cancer Care Specialists of Illinois - Decatur

    Decatur, Illinois, 62526, United States

  • Cancer Center of Kansas - Wichita

    Wichita, Kansas, 67214, United States

  • Cancer Center of Kansas-Wichita Medical Arts Tower

    Wichita, Kansas, 67208, United States

  • Cancer Centers of Southwest Oklahoma Research

    Lawton, Oklahoma, 73505, United States

  • Carle Cancer Center

    Urbana, Illinois, 61801, United States

  • Carle Physician Group-Effingham

    Effingham, Illinois, 62401, United States

  • Carle Physician Group-Mattoon/Charleston

    Mattoon, Illinois, 61938, United States

  • Carle at The Riverfront

    Danville, Illinois, 61832, United States

  • Centralia Oncology Clinic

    Centralia, Illinois, 62801, United States

  • City of Hope Comprehensive Cancer Center

    Duarte, California, 91010, United States

  • CommonSpirit Cancer Center Mercy

    Durango, Colorado, 81301, United States

  • CommonSpirit Saint Anthony Hospital Cancer Center

    Lakewood, Colorado, 80228, United States

  • CommonSpirit Saint Joseph Hospital - Bardstown

    Bardstown, Kentucky, 40004, United States

  • CommonSpirit Saint Joseph Hospital London

    London, Kentucky, 40741, United States

  • CommonSpirit Saint Joseph Medical Center - East Lexington

    Lexington, Kentucky, 40509, United States

  • Commonwealth Cancer Center-Corbin

    Corbin, Kentucky, 40701, United States

  • Community Hospital of Anaconda

    Anaconda, Montana, 59711, United States

  • Community Medical Center

    Missoula, Montana, 59804, United States

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada, 89148, United States

  • Comprehensive Cancer Centers of Nevada - Central Valley

    Las Vegas, Nevada, 89169, United States

  • Comprehensive Cancer Centers of Nevada - Henderson

    Henderson, Nevada, 89052, United States

  • Comprehensive Cancer Centers of Nevada - Northwest

    Las Vegas, Nevada, 89128, United States

  • Comprehensive Cancer Centers of Nevada-Summerlin

    Las Vegas, Nevada, 89144, United States

  • Crossroads Cancer Center

    Effingham, Illinois, 62401, United States

  • Decatur Memorial Hospital

    Decatur, Illinois, 62526, United States

  • Franciscan Research Center-Northwest Medical Plaza

    Tacoma, Washington, 98405, United States

  • Fred Hutchinson Cancer Center

    Seattle, Washington, 98109, United States

  • Fred and Pamela Buffett Cancer Center - Kearney

    Kearney, Nebraska, 68845, United States

  • Good Samaritan Hospital - Cincinnati

    Cincinnati, Ohio, 45220, United States

  • Great Falls Clinic

    Great Falls, Montana, 59405, United States

  • Greater Regional Medical Center

    Creston, Iowa, 50801, United States

  • Harrison HealthPartners Hematology and Oncology-Poulsbo

    Poulsbo, Washington, 98370, United States

  • Hematology and Oncology Consultants PC

    Omaha, Nebraska, 68122, United States

  • Henry Ford Cancer Institute-Downriver

    Brownstown, Michigan, 48183, United States

  • Henry Ford Hospital

    Detroit, Michigan, 48202, United States

  • Henry Ford Macomb Health Center - Shelby Township

    Shelby, Michigan, 48315, United States

  • Henry Ford Macomb Hospital-Clinton Township

    Clinton Township, Michigan, 48038, United States

  • Henry Ford West Bloomfield Hospital

    West Bloomfield, Michigan, 48322, United States

  • Highline Medical Center-Main Campus

    Burien, Washington, 98166, United States

  • Idaho Urologic Institute-Meridian

    Meridian, Idaho, 83642, United States

  • Illinois CancerCare-Bloomington

    Bloomington, Illinois, 61704, United States

  • Illinois CancerCare-Canton

    Canton, Illinois, 61520, United States

  • Illinois CancerCare-Carthage

    Carthage, Illinois, 62321, United States

  • Illinois CancerCare-Eureka

    Eureka, Illinois, 61530, United States

  • Illinois CancerCare-Galesburg

    Galesburg, Illinois, 61401, United States

  • Illinois CancerCare-Kewanee Clinic

    Kewanee, Illinois, 61443, United States

  • Illinois CancerCare-Macomb

    Macomb, Illinois, 61455, United States

  • Illinois CancerCare-Ottawa Clinic

    Ottawa, Illinois, 61350, United States

  • Illinois CancerCare-Pekin

    Pekin, Illinois, 61554, United States

  • Illinois CancerCare-Peoria

    Peoria, Illinois, 61615, United States

  • Illinois CancerCare-Peru

    Peru, Illinois, 61354, United States

  • Illinois CancerCare-Princeton

    Princeton, Illinois, 61356, United States

  • Jewish Hospital

    Louisville, Kentucky, 40202, United States

  • Jewish Hospital Medical Center South

    Shepherdsville, Kentucky, 40165, United States

  • Kootenai Clinic Cancer Services - Post Falls

    Post Falls, Idaho, 83854, United States

  • Kootenai Clinic Cancer Services - Sandpoint

    Sandpoint, Idaho, 83864, United States

  • Kootenai Health - Coeur d'Alene

    Coeur d'Alene, Idaho, 83814, United States

  • Lawrence Memorial Hospital

    Lawrence, Kansas, 66044, United States

  • Logan Health Medical Center

    Kalispell, Montana, 59901, United States

  • Longmont United Hospital

    Longmont, Colorado, 80501, United States

  • Lyndon Baines Johnson General Hospital

    Houston, Texas, 77026-1967, United States

  • MU Health Care Goldschmidt Cancer Center

    Jefferson City, Missouri, 65109, United States

  • Mary Greeley Medical Center

    Ames, Iowa, 50010, United States

  • Mayo Clinic Hospital in Arizona

    Phoenix, Arizona, 85054, United States

  • Mayo Clinic in Arizona

    Scottsdale, Arizona, 85259, United States

  • Mayo Clinic in Rochester

    Rochester, Minnesota, 55905, United States

  • McFarland Clinic - Ames

    Ames, Iowa, 50010, United States

  • McFarland Clinic - Boone

    Boone, Iowa, 50036, United States

  • McFarland Clinic - Jefferson

    Jefferson, Iowa, 50129, United States

  • McFarland Clinic - Marshalltown

    Marshalltown, Iowa, 50158, United States

  • McFarland Clinic - Trinity Cancer Center

    Fort Dodge, Iowa, 50501, United States

  • Medical University of South Carolina

    Charleston, South Carolina, 29425, United States

  • Memorial GYN Plus

    Ooltewah, Tennessee, 37363, United States

  • Memorial Hospital

    Chattanooga, Tennessee, 37404, United States

  • Memorial Hospital of Carbondale

    Carbondale, Illinois, 62902, United States

  • Mercy Cancer Center - Cape Girardeau

    Cape Girardeau, Missouri, 63703, United States

  • Mercy Cancer Center-West Lakes

    Clive, Iowa, 50325, United States

  • Mercy Medical Center

    Durango, Colorado, 81301, United States

  • Mercy Medical Center - Des Moines

    Des Moines, Iowa, 50314, United States

  • Mercy Medical Center-West Lakes

    West Des Moines, Iowa, 50266, United States

  • Methodist Medical Center of Illinois

    Peoria, Illinois, 61636, United States

  • Midlands Community Hospital

    Papillion, Nebraska, 68046, United States

  • Missouri Baptist Medical Center

    St Louis, Missouri, 63131, United States

  • Missouri Baptist Sullivan Hospital

    Sullivan, Missouri, 63080, United States

  • Mountain Blue Cancer Care Center

    Golden, Colorado, 80401, United States

  • Nebraska Cancer Specialists/Oncology Hematology West PC

    Grand Island, Nebraska, 68803, United States

  • Northwest Medical Specialties PLLC

    Tacoma, Washington, 98405, United States

  • OSF Saint Francis Medical Center

    Peoria, Illinois, 61637, United States

  • OSF Saint Francis Radiation Oncology at Pekin

    Pekin, Illinois, 61554, United States

  • OSF Saint Francis Radiation Oncology at Peoria Cancer Center

    Peoria, Illinois, 61615, United States

  • Ochsner Medical Center Jefferson

    New Orleans, Louisiana, 70121, United States

  • Oncology Las Vegas - Henderson

    Henderson, Nevada, 89074, United States

  • OptumCare Cancer Care at Charleston

    Las Vegas, Nevada, 89102, United States

  • OptumCare Cancer Care at Fort Apache

    Las Vegas, Nevada, 89183, United States

  • OptumCare Cancer Care at MountainView

    Las Vegas, Nevada, 89128, United States

  • Overlake Medical Center

    Bellevue, Washington, 98004, United States

  • PCR Oncology

    Arroyo Grande, California, 93420, United States

  • Parkland Health Center-Bonne Terre

    Bonne Terre, Missouri, 63628, United States

  • Penrose-Saint Francis Healthcare

    Colorado Springs, Colorado, 80907, United States

  • Pulmonary Medicine Center of Chattanooga-Hixson

    Hixson, Tennessee, 37343, United States

  • Radiation Oncology Associates

    Reno, Nevada, 89509, United States

  • Radiation Oncology Centers of Nevada Central

    Las Vegas, Nevada, 89106, United States

  • Radiation Oncology Centers of Nevada Southeast

    Las Vegas, Nevada, 89119, United States

  • Renown Regional Medical Center

    Reno, Nevada, 89502, United States

  • Rocky Mountain Cancer Centers - Pueblo

    Pueblo, Colorado, 81008, United States

  • Rocky Mountain Cancer Centers-Lakewood

    Lakewood, Colorado, 80228, United States

  • Rocky Mountain Cancer Centers-Longmont

    Longmont, Colorado, 80501, United States

  • Rocky Mountain Cancer Centers-Parker

    Parker, Colorado, 80138, United States

  • Rocky Mountain Cancer Centers-Penrose

    Colorado Springs, Colorado, 80907, United States

  • Rocky Mountain Cancer Centers-Thornton

    Thornton, Colorado, 80260, United States

  • Rush-Copley Healthcare Center

    Yorkville, Illinois, 60560, United States

  • Rush-Copley Medical Center

    Aurora, Illinois, 60504, United States

  • SIH Cancer Institute

    Carterville, Illinois, 62918, United States

  • Saint Alphonsus Cancer Care Center-Boise

    Boise, Idaho, 83706, United States

  • Saint Alphonsus Cancer Care Center-Caldwell

    Caldwell, Idaho, 83605, United States

  • Saint Alphonsus Cancer Care Center-Nampa

    Nampa, Idaho, 83687, United States

  • Saint Clare Hospital

    Lakewood, Washington, 98499, United States

  • Saint Elizabeth Hospital

    Enumclaw, Washington, 98022, United States

  • Saint Elizabeth Regional Medical Center

    Lincoln, Nebraska, 68510, United States

  • Saint Francis Hospital

    Federal Way, Washington, 98003, United States

  • Saint Francis Medical Center

    Cape Girardeau, Missouri, 63703, United States

  • Saint Joseph Medical Center Hematology and Oncology - Silverdale

    Silverdale, Washington, 98383, United States

  • Saint Joseph Radiation Oncology Resource Center

    Lexington, Kentucky, 40504, United States

  • Saint Joseph Regional Cancer Center

    Bryan, Texas, 77802, United States

  • Saint Mary Corwin Medical Center

    Pueblo, Colorado, 81004, United States

  • Saint Mary's Regional Medical Center

    Reno, Nevada, 89503, United States

  • Saint Peter's Community Hospital

    Helena, Montana, 59601, United States

  • Sainte Genevieve County Memorial Hospital

    Sainte Genevieve, Missouri, 63670, United States

  • Saints Mary and Elizabeth Hospital

    Louisville, Kentucky, 40215, United States

  • Southern Illinois University School of Medicine

    Springfield, Illinois, 62702, United States

  • Southwest Illinois Health Services LLP

    Swansea, Illinois, 62226, United States

  • Springfield Clinic

    Springfield, Illinois, 62702, United States

  • Springfield Memorial Hospital

    Springfield, Illinois, 62781, United States

  • The Carle Foundation Hospital

    Urbana, Illinois, 61801, United States

  • TriHealth Cancer Institute-Anderson

    Cincinnati, Ohio, 45255, United States

  • TriHealth Cancer Institute-Westside

    Cincinnati, Ohio, 45247, United States

  • UI Health Care Mission Cancer and Blood - Laurel Clinic

    Des Moines, Iowa, 50314, United States

  • UI Health Care Mission Cancer and Blood - West Des Moines Clinic

    Clive, Iowa, 50325, United States

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania, 15232, United States

  • UT MD Anderson - League City

    League City, Texas, 77573, United States

  • UT MD Anderson - Sugar Land

    Sugar Land, Texas, 77478, United States

  • UT MD Anderson - The Woodlands

    Conroe, Texas, 77384, United States

  • UT MD Anderson - West Houston

    Houston, Texas, 77079, United States

  • UT MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • UT Southwestern Clinical Center at Richardson/Plano

    Richardson, Texas, 75080, United States

  • UT Southwestern/Simmons Cancer Center-Dallas

    Dallas, Texas, 75390, United States

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California, 95817, United States

  • University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma, 73104, United States

  • University of Virginia Cancer Center

    Charlottesville, Virginia, 22908, United States

  • University of Washington Medical Center - Montlake

    Seattle, Washington, 98195, United States

  • UofL Health Medical Center Northeast

    Louisville, Kentucky, 40245, United States

  • Valley Medical Center

    Renton, Washington, 98055, United States

  • Valley Radiation Oncology

    Peru, Illinois, 61354, United States

  • Welch Cancer Center

    Sheridan, Wyoming, 82801, United States

  • Western Illinois Cancer Treatment Center

    Galesburg, Illinois, 61401, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.